In this issue of Blood, Stein et al1 demonstrate the feasibility and clinical efficacy of targeted inhibition of mutant isocitrate dehydrogenase 2 (IDH2) in patients with acute myeloid leukemia (AML). In a related paper, Amatangelo et al2 investigate mechanisms of response in samples derived from the same patients.

Additional Metadata
Persistent URL dx.doi.org/10.1182/blood-2017-06-790394, hdl.handle.net/1765/101549
Journal Blood
Citation
Wouters, B.J. (2017). Hitting the target in IDH2 mutant AML. Blood (Vol. 130, pp. 693–694). doi:10.1182/blood-2017-06-790394